The rate of HIV infection continues to climb globally. Around 40 million people live with HIV-1, the most common HIV strain. While symptoms can now be better managed with lifelong treatment, there is ...
On the left is integrase in its “intasome” structure of four identical four-part complexes (pink) that connect to create one 16-part complex that locks around viral DNA (blue). On the right is ...
The FDA granted priority review, with a decision expected by June 19, 2025. LEN represents a novel class of HIV therapies by targeting the viral capsid, a multifunctional protein essential for HIV ...
Nucleoside reverse transcriptase translocation inhibitors (NRTTIs) are a novel class of antiretroviral agents that inhibit HIV replication by targeting the viral reverse transcriptase enzyme and ...
For the first time, scientists have captured how new antiviral drugs halt the herpes virus in real time as it tries to replicate.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results